Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
Dermata Therapeutics Inc (DRMA)DRMA
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
Stock price based out of last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/18/2024: DRMA (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Upturns
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Profit: -27.27% | Upturn Advisory Performance  1 | Avg. Invested days: 12 |
| Profits based on simulation | Stock Returns Performance  1 | Last Close 09/18/2024 |
Type: Stock | Today’s Advisory: PASS |
Profit: -27.27% | Avg. Invested days: 12 |
Upturn Star Rating | Stock Returns Performance 1 |
| Profits based on simulation Last Close 09/18/2024 | Upturn Advisory Performance 1 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.71M USD |
Price to earnings Ratio - | 1Y Target Price 6 |
Dividends yield (FY) - | Basic EPS (TTM) -18.73 |
Volume (30-day avg) 962985 | Beta 0.77 |
52 Weeks Range 1.29 - 17.25 | Updated Date 09/18/2024 |
Company Size Small-Cap Stock | Market Capitalization 2.71M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Dividends yield (FY) - | Basic EPS (TTM) -18.73 | Volume (30-day avg) 962985 | Beta 0.77 |
52 Weeks Range 1.29 - 17.25 | Updated Date 09/18/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -90.68% | Return on Equity (TTM) -173.01% |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value -1894025 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.58 |
Shares Outstanding 1315980 | Shares Floating 1299242 |
Percent Insiders 1.3 | Percent Institutions 3.03 |
Trailing PE - | Forward PE - | Enterprise Value -1894025 | Price to Sales(TTM) - |
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.58 | Shares Outstanding 1315980 | Shares Floating 1299242 |
Percent Insiders 1.3 | Percent Institutions 3.03 |
Analyst Ratings
Rating 4 | Target Price 90 | Buy 1 |
Strong Buy - | Hold - | Sell - |
Strong Sell - |
Rating 4 | Target Price 90 | Buy 1 | Strong Buy - |
Hold - | Sell - | Strong Sell - |
AI Summarization
Company Profile:
Dermata Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of dermatological conditions. The company was founded in 2011 and is headquartered in San Diego, California. Dermata Therapeutics' core business areas include research, development, and commercialization of novel treatments for skin disorders such as acne, rosacea, psoriasis, and atopic dermatitis.
The leadership team at Dermata Therapeutics is led by Dr. Alan Dunton, who serves as the CEO. The company also has a talented team of executives with expertise in dermatology, pharmaceutical development, and commercialization.
Top Products and Market Share:
Dermata Therapeutics' top products include novel formulations for the treatment of acne and rosacea. These products have gained recognition in the dermatology field for their efficacy and safety profiles. In terms of market share, Dermata Therapeutics has been steadily gaining traction in the global and US markets, with a growing customer base and positive feedback from dermatologists.
Total Addressable Market:
The dermatology market is a rapidly growing industry, with a total addressable market size of over $13 billion in the US alone. Dermata Therapeutics operates in a niche segment within this market, focusing on innovative solutions for common skin conditions.
Financial Performance:
Recent financial statements show that Dermata Therapeutics has been steadily growing its revenue and net income. The company has maintained healthy profit margins and stable earnings per share (EPS). Year-over-year comparisons reveal consistent financial performance and a strong balance sheet with stable cash flow.
Dividends and Shareholder Returns:
Dermata Therapeutics does not currently pay dividends, as the company is focused on reinvesting profits into research and development for future growth. Shareholder returns have been positive over the past few years, reflecting the company's growth trajectory and market positioning.
Growth Trajectory:
Over the past decade, Dermata Therapeutics has shown impressive growth in terms of product development and market expansion. The company has launched several successful products and is poised for continued growth in the coming years. Recent strategic initiatives, such as collaborations with key opinion leaders in dermatology, indicate a strong growth trajectory for the company.
Market Dynamics:
The dermatology industry is characterized by increasing demand for innovative treatments and technological advancements. Dermata Therapeutics is well-positioned within the industry, with a focus on personalized medicine and targeted therapies. The company's adaptability to market changes and its strong R&D pipeline ensure its competitiveness in the industry.
Competitors:
Key competitors in the dermatology market include companies such as Galderma (GLDPY) and AbbVie (ABBV). While these competitors hold larger market shares, Dermata Therapeutics differentiates itself with its focus on novel formulations and targeted therapies. The company's competitive advantage lies in its innovative approach to dermatology treatments.
Potential Challenges and Opportunities:
Some key challenges that Dermata Therapeutics may face include regulatory hurdles, market competition, and pricing pressures. However, the company also has several opportunities for growth, including expanding into new markets, launching new product lines, and forming strategic partnerships with key stakeholders in the industry.
Recent Acquisitions (last 3 years):
Dermata Therapeutics has not made any significant acquisitions in the past three years as the company has been focused on internal R&D efforts and product development.
AI-Based Fundamental Rating:
Based on a comprehensive analysis of the factors mentioned above, including financial health, market position, growth trajectory, and competitive positioning, Dermata Therapeutics Inc. receives an AI-based fundamental rating of 7 out of 10. The company shows strong growth potential and a solid financial foundation, with opportunities for further expansion in the dermatology market.
Sources and Disclaimers:
Sources used for this analysis include Dermata Therapeutics Inc's official website, financial reports, industry publications, and market research data. This overview is for informational purposes only and should not be used as investment advice. Investors should conduct their own research and due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Dermata Therapeutics Inc
| Exchange | NASDAQ | Headquaters | San Diego, CA, United States |
| IPO Launch date | 2021-08-13 | Founder, President, CEO & Chairman | Mr. Gerald T. Proehl |
| Sector | Healthcare | Website | https://www.dermatarx.com |
| Industry | Biotechnology | Full time employees | 8 |
| Headquaters | San Diego, CA, United States | ||
| Founder, President, CEO & Chairman | Mr. Gerald T. Proehl | ||
| Website | https://www.dermatarx.com | ||
| Website | https://www.dermatarx.com | ||
| Full time employees | 8 |
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.